UBS Group’s Celularity Inc CELUW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | – | Sell |
-5,278
| Closed | -$21 | – | 11231 |
|
|
2026
Q2 | $21 | Buy |
5,278
+3,063
| +138% | +$21 | ﹤0.01% | 10269 |
|
|
2026
Q1 | $22 | Buy |
2,215
+302
| +16% | +$3 | ﹤0.01% | 10279 |
|
|
2025
Q4 | $31 | Buy |
1,913
+600
| +46% | +$15 | ﹤0.01% | 10315 |
|
|
2025
Q3 | $46 | Buy |
+1,313
| New | +$64 | ﹤0.01% | 10035 |
|
|
2024
Q4 | – | Sell |
-168
| Closed | -$2 | – | 9964 |
|
|
2024
Q3 | $2 | Buy |
168
+68
| +68% | +$1 | ﹤0.01% | 9409 |
|
|
2024
Q2 | $2 | Buy |
+100
| New | +$3 | ﹤0.01% | 9417 |
|
|
2024
Q1 | – | Sell |
-38,556
| Closed | -$1.54K | – | 9383 |
|
|
2023
Q4 | $1.54K | Buy |
+38,556
| New | +$663 | ﹤0.01% | 8280 |
|
|
2023
Q1 | – | Sell |
-18,446
| Closed | -$1.29K | – | 9655 |
|
|
2022
Q4 | $1.29K | Buy |
18,446
+18,438
| +230,475% | +$4.04K | ﹤0.01% | 9903 |
|
|
2022
Q3 | $0 | Hold |
8
| – | – | ﹤0.01% | 10385 |
|
|
2022
Q2 | $0 | Sell |
8
-3,566
| -100% | -$3.51K | ﹤0.01% | 10367 |
|
|
2022
Q1 | $5K | Buy |
3,574
+3,566
| +44,575% | +$2.9K | ﹤0.01% | 9104 |
|
|
2021
Q4 | $0 | Hold |
8
| – | – | ﹤0.01% | 10282 |
|
|
2021
Q3 | $0 | Hold |
8
| – | – | ﹤0.01% | 9580 |
|
|
2021
Q2 | $0 | Buy |
+8
| New | +$10 | ﹤0.01% | 9410 |
|
|
2021
Q1 | – | Sell |
-3,067
| Closed | -$9K | – | 9025 |
|
|
2020
Q4 | $9K | Buy |
+3,067
| New | +$5.74K | ﹤0.01% | 7552 |
|
UBS Group's CELUW Position: Q3 2026 in Review
UBS Group sold out of Celularity Inc (CELUW) in Q3 2026, closing a stake of 5,278 shares — an estimated $21 sold.
UBS Group first reported a position in CELUW in Q4 2020 and held it in 15 quarters. The position peaked at $9K in Q4 2020. 0 funds tracked by Wall St. Rank hold CELUW as of Q3 2026.
- UBS Group reported no remaining Celularity Inc position as of Q3 2026 after selling out during the quarter.
- UBS Group sold 5,278 Celularity Inc shares in Q3 2026, an estimated $21.
- UBS Group first reported a position in Celularity Inc in Q4 2020 and held it in 15 quarters.
- UBS Group's Celularity Inc position peaked at $9K in Q4 2020.
- 0 funds tracked by Wall St. Rank held Celularity Inc as of Q3 2026.
Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.